- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
New Hope for Head and Neck Cancer Patients Ineligible for Cisplatin
Head and neck squamous cell carcinoma (LAHNSCC) is a type of cancer that affects the head and neck area. It is often treated with radiotherapy, either as the main treatment or after surgery to remove the cancer. Adding platinum chemotherapy, like cisplatin, to radiotherapy can improve the chances of successfully treating the cancer and the patient's overall survival. When cisplatin chemotherapy is administered together with radiotherapy, it improves tumor control, decreases the chances of it coming back thus improving life expectancy. This is largely due to its property of radiosensitizer. However, cisplatin can cause serious side effects, including kidney damage and hearing loss, which can make it unsuitable for some patients. Due to this unmet need in such patients an alternative radiosensitizer was required. However, which radiosensitizer to be used was unknown.
In a randomized clinical trial assessing the efficacy of docetaxel, a chemotherapy drug, as an alternative radiosensitizer, researchers evaluated patients with locally advanced head and neck cancer who were treated with radiotherapy alone or after surgery and required cisplatin but were unfit for it due to comorbidities such as hearing loss or tinnitus, kidney problems, heart problems, or multiple uncontrolled conditions. A total of 356 patients were selected for the study and received either radiotherapy or radiotherapy with a weekly small dose of docetaxel for six or seven doses. The study found that the addition of docetaxel resulted in a statistically significant decrease in the likelihood of disease recurrence, an improvement in quality of life, and an increase in overall survival. The addition of docetaxel led to an improvement of disease control by nearly 12% and an average increase in lifespan of 10 months.
The publication of these results in the Journal of Clinical Oncology, a leading journal from the American Society of Clinical Oncology (ASCO), established a new standard of care for cisplatin-unfit patients. Today, patients requiring radiotherapy and those who are unfit for cisplatin need to be treated with docetaxel and radiotherapy. This study is one of the first randomized studies conducted in this setting, not only in India but also globally.
With the development of this new regimen, a major unsolved problem in head and neck cancer has been addressed. Docetaxel is readily available in India, and the development of this therapy has made an accessible, affordable, and scientifically validated treatment option available for cisplatin-unfit patients. However, the use of docetaxel can lead to adverse events and has a learning curve, so experienced head and neck medical oncologists who are well versed in managing the side effects of chemotherapy and radiation should administer it.
This important study throws light on a more cost-effective treatment option for head and neck cancer patients who can't take cisplatin. It demonstrates how docetaxel can improve the chances of being disease-free and living longer compared to only receiving radiation treatment in patients who cannot be given cisplatin and also highlights the importance of continued research into alternative treatments for head and neck cancer.
Reference:
Here's the study: https://ascopubs.org/doi/abs/10.1200/JCO.22.00980.
Dr Vijay Patil, MBBS, MD(Radiation Oncology) is a Consultant (Medical Oncology) at P.D. Hinduja Hospital and Research Centre, Khar. He has over 16 years of experience as an oncologist and has managed a wide array of conditions. Dr Vijay Patil has one of the largest experiences in administering and managing ‘Immunotherapy’ as a treatment regimen for cancer. Dr Patil has attained national coverage and global acclaim for this research. In addition, he has pioneered the development of chemotherapy, metronomic, immunotherapy and targeted therapy in Head & Neck Cancers, Brain tumours, and Thoracic and Urology tumours. Dr Patil has conceptualized and authored over 500 publications in his domains of speciality. He is the principal investigator for over 30 clinical trials (and he has led pioneering research that has transformed treatment paradigms and has been published by the leading oncology journals in the world.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751